ABSTRACT Aims To determine the incidence and associated factors of hypertension and dyslipidemia improvement at the time of type 2 diabetes remission in clinical settings. Materials and Methods Among 53 560 participants with type 2 diabetes in a clinical database, 3677 achieved remissions during follow‐up. In the complete‐case dataset, 2229 people aged > 18 years with type 2 diabetes remission were enrolled. Hypertension improvement was defined as systolic blood pressure < 130 mmHg and diastolic blood pressure < 80 mmHg without any blood pressure‐lowering drugs. Dyslipidemia improvement was defined as high‐density lipoprotein cholesterol (HDL‐C) ≥ 1.0 mmol/L and non‐HDL‐C < 3.9 mmol/L without any lipid‐lowering drugs. Factors associated with improvement in hypertension and/or dyslipidemia were evaluated using logistic regression analysis in the multiple imputation dataset. Results Of the enrolled people, 74% and 62% had hypertension and dyslipidemia, respectively, and 46% had both. At the time of type 2 diabetes remission, approximately 25% of people with either hypertension or dyslipidemia at baseline exhibited improvement in these conditions. Moreover, 79 (8%) of people with both hypertension and dyslipidemia experienced improvement upon type 2 diabetes remission. Lower baseline BMI was associated with hypertension improvement, while higher baseline HbA1c was associated with dyslipidemia improvement. Additionally, younger age and a ≥ 10% BMI reduction were consistently associated with the improvement in hypertension, dyslipidemia and both improvement. Conclusions Our findings implied that continuous management of multifactorial intervention, especially weight control, is important for greater control of comorbidities in people with type 2 diabetes regardless of the remission status.
KHIN et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: